chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sore left arm/ pain in his left arm.; The patient also had reaction to the Band-Aid that was put on his left arm after the Pfizer COVID third booster; They gave him the 3rd COVID booster shot on 28Sep2021; They gave him the 3rd COVID booster shot on 28Sep2021; This is a spontaneous report from a contactable consumer (patient). A 55-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 28Sep2021 (at the age of 55-year-old) (Lot number and expiration date was not reported) as DOSE 3 (BOOSTER), SINGLE for COVID-19 immunization. The patient did not have medical history and concomitant medications. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, on an unspecified date in Dec2020 (at the age of 54-year-old) (Lot number and expiration date was not reported) as DOSE 1, SINGLE and on an unspecified date in Jan2021 (at the age of 54-year-old) (Lot number and expiration date was not reported) as DOSE 2, SINGLE for COVID-19 immunization. On 28Sep2021, the patient had sore left arm. The patient also had reaction to the Band-Aid that was put on his left arm after the Pfizer COVID third booster. It caused a reaction on his left arm. It was like getting a tattoo. He only had a reaction from the Band-Aid on the 3rd booster. He got it in the morning around 10 to 10:30. Then, about 2 to 2:30, he took the Band-Aid off, and there was a mark on the band aid. It was like a strip mark. It was like an adhesive mark on his left arm. He peeled the adhesive off. In a couple of days, it was itchy. He went to the occupation health department for assessment. They told him to wash it with saline water and put hydrocortisone 1% on it. They told him to go to his Primary care physician at hospital. He asked if he could take Hydrocortisone 2.5% on it, and they said yes. He has continued to do that. The mark was getting lighter but it was still there. There was no other reaction or sign of reaction to the vaccine 3rd dose. The patient received treatment with paracetamol (TYLENOL). The patient had a couple days of pain in his left arm. The patient recovered from sore arm. The outcome of other events was unknown.  Information on lot/ batch number has been requested.
Felt lightheaded after receiving Tdap/immediately & was placed supine - felt better & left our clinic but then had near syncopal episode upon return to work area. "Felt shaky all over" as though she could not breathe. VS in ED 151/75-84-18 O2 sat 98% on room air. Was evaluated in ED & discharged. Sx likely were R/T vagal response (no rash or resp sx.). Discharged to home after ED eval.
Patient experienced redness and swelling on her arm located about 4 in below injection site. Patient stated it was the size of a tennis ball and lasted about 3 days.
Two hours afTer injecTion came down wiTh a fever. The nexT 2 days was in bed. SlepT for 6 hrs aT a Time. Did noT eaT or drink anyThing for 2 days. AfTer ThaT I had To force Myself To eaT. Three day LaTer was expose to Covid 19. No energy, sleep a loT, no appeiTaTe, no sense of smell, no sense of TasTe. After being informed of being exposed to Covid 19 I self QuarTined for 14 days. I am feeling much beTTer; buT sTill have no sense of sMell and no sense of TasTe.
LEG PAIN; HEADACHE; DIZZINESS; NECK PAIN; FEVER; This spontaneous report received from a parent concerned a 21 year old male. The patient's weight was 130 pounds, and height was 68 inches. The patient's concurrent conditions included non alcohol user, and non smoker, and other pre-existing medical conditions included patient had no known drug allergies. no drug abuse or illicit drug usage. medical history the family had a history of vein issues, and the mother had blood clots before. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 11-JUN-2021 for prophylactic vaccination. No concomitant medications were reported. On 11-JUN-2021, the subject experienced neck pain. On 11-JUN-2021, the subject experienced fever. On 12-JUN-2021, the subject experienced dizziness. On 12-JUN-2021, the subject experienced headache. On 13-JUN-2021, the subject experienced leg pain. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on 12-JUN-2021, and had not recovered from dizziness, headache, leg pain, and neck pain. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard  procedure as the case  assessed as non serious
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, reported as since 20-APR-2017, the patients were vaccinated with improperly stored doses of VARIVAX lot# L035129 with expiration date 14-SEP-2017, lot# M033904 with expiration date 20-JUL-2018, lot# M000996 with expiration date 07-JAN-2018, lot# L035129 with expiration date 14-SEP-2017, lot# M025865 with expiration date 24-MAY-2018 and lot# M010484 with expiration date 01-MAR-2018 (dose and route of administration were not reported). On 25-APR-2017, the patients were vaccinated with improperly stored doses of VARIVAX lot # M025864, expiration date 24-APR-2018 (dose and route of administration were not reported). All vaccines were reconstituted with properly stored sterile diluent (lot# and expiration date were not provided). There was no adverse effect reported. From 20-APR-2017 to 18-MAY-2017, administered doses of vaccines experienced the temperature excursion between - 9 degrees Celsius and 8 degrees Celsius for about 315 hours and between -14 degrees Celsius and -10 degrees Celsius for about 376 hours. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-00503517-1705USA009632.
Chills, felt like i had a fever, headache, normal joint pain, Joint pain eventually turned into lupus flaring in the pelvis, , intense pain in the scalp (felt like i could not touch my hair), vomiting
the injection site is very painful; chills; body aches; swollen lymph nodes; This is a spontaneous report from a contactable other healthcare professional (patient).  A 22-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), lot number: EL1284, via an unspecified route of administration in Left arm from 04Jan2021 03:45 to 04Jan2021 03:45 as SINGLE DOSE COVID-19 immunisation.  The patient medical history was not reported.  The patient's concomitant medications were not reported. On 05Jan2021 04:00 AM, the injection site is very painful, chills, body aches, and swollen lymph nodes (no sore throat). The outcome of the event was unknown. No treatment was received for the events.
Headaches as of the evening after receiving vaccine booster.  Two weeks after , I?m still experiencing headaches I never had before
PATIENT REPORTS SWELLING ROUND THE RIGHT SIDE OF HER MOUTH, PARTIAL FACIAL PARALYSIS, AND RIGHT-SIDE PARTIAL PARALYSIS AND/OR WEAKNESS.
This spontaneous case, initially received from a pharmacist on 24-Sep-2018, concerning a 65-year-old, elderly patient of an unspecified gender. The patient's medical history and concomitant medications were not available. Since 03-Sep-2018, the refrigerator's temperature fluctuated above 47F and FLUCELVAX QIVc vaccine exposed to temperatures in the range of 47F to 50.9F. On 05-Sep-2018, the patient was administered FLUCELVAX QIVc (dose: 0.5 ml, route of administration: intramuscular, anatomical location, batch number and expiry date: not reported) which underwent temperature excursion. The patient did not experience any adverse drug reaction after the vaccination. The reporter assessed the case as non-serious. This case 201803871 cross-linked to original case 201804076 due to the same reporter. Non-significant follow-up received from the reporter on 14-Nov-2018: Info Number (SEQ18-04086) was updated in the additional information tab. No changes were made in the narrative.
I was sleepy and achy all day Sunday; which did not have me concerned until Monday when I noticed my left trapezius muscle was very sore, I then noticed it had swelled to 3 times the size of the other side, then swelling was progressing toward the front of my neck around the clavicle. I took ibuprofen for a headache I woke with, the swelling started to subside as a result of it. The pain was mostly gone by evening. Last night I was getting stuffy, I still feel like I have a bit of a cold; achy, mucous forming mostly in my left nostril along with sore throat. This is the first reaction I have had to a flu shot, although last year I had a strong reaction to my 2nd dose of the Shingrex; with severe chills and shaking.
Upon injecting MCV4 pt became unresponsive, toppled over, no jerking, staring off, generalized and 4 ext. tonic yet breathing, no color changes X less than 10 seconds. Pt. became responsive spontaneously. Was slightly drowsy and amnestic for a few minutes (les than 5 minutes).
31JAN97 cold sx-runny nose, t97.7;1FEB97 t99, pt given med;cult ordered 4FEB97; 12FEB97 Robitussin;28FEB97 med given x 7 days;
This is a spontaneous report from a contactable consumer (patient). This female patient of unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) in the morning of 17Apr2021 as single dose for COVID-19 immunization. Medical history and concomitant medications were not provided. The patient got the first dose on 17Apr2021 morning, she was fine that day, although at night she had arm pain. The next day (18Apr2021), her arm pain continued and she felt very tired. In morning of 19Apr2021, she began having vertigo, she had it since 19Apr2021 until the reporting time, patient asked is it normal after the vaccine? Previously she had no vertigo. She got dizzy, she felt dizzy when she turned around on an unspecified date in Apr2021. Outcome of the event vertigo was not recovered, while other events was unknown. This report was assessed as non-serious.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This spontaneous report was received from a physician refers to a female patient of unknown age. There was no information on the patient's medical history, concomitant medications, drug reactions and allergies provided. On 02-NOV-2002, the patient was vaccinated with hepatitis b vaccine (recombinant) (manufacturer unknown) for prophylaxis (route of administration, lot number and expiration date were not provided). On 05-DEC-2002, the patient received dose of RECOMBIVAX. On 10-MAY-2003, the patient received another dose of RECOMBIVAX. On 22-OCT-2016, the patient tested negative for HBsAG. On approximately 23-APR-2018 (reported as week ago), the patient tested negative for HBsAG again. The outcome of the event was reported as not recovered. The relatedness between the event and RECOMBIVAX was not provided.
Information has been received from a physician concerning an approximately 17 year old female patient with a history of bulimia who in July 2007, was vaccinated with her first dose of GARDASIL (lot # not reported). Concomitant therapy included DEPO-PROVERA. The physician reported that the patient after receiving her second dose of GARDASIL in September 2007 lost 30-40 pounds. Therapy with GARDASIL was discontinued and not reintroduced. At the time of report, the patient's outcome was unknown. The patient did not seek medical attention. Additional information is not expected.
gastro issues; light headed; This case was reported by a consumer and described the occurrence of gastrointestinal disorder in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 12th August 2021, the patient received Shingles vaccine. In August 2021, less than a week after receiving Shingles vaccine, the patient experienced gastrointestinal disorder and light headedness. On an unknown date, the outcome of the gastrointestinal disorder and light headedness were not recovered/not resolved.   It was unknown if the reporter considered the gastrointestinal disorder and light headedness to be related to Shingles vaccine.  Additional details were provided as follows: The patient self reported the case. The age at vaccination was not reported. The patient received Shingrix vaccine and experienced gastro issues and light headed. The patient wanted to know how long would this last. The follow up would not be possible as no contact details were available.
Subsequent to receiving one dose of varicella virus vaccine live on 9/26/95, the pt developed varicella illness with greater than 50 lesions but otherwise mild symptoms on 4/15/99. Prior to the onset of the episode, the pt was exposed to varicella from a sibling that had also had Varivax before.
Loss of balance, dizziness,ringing ears, slight headache, pressure at back of head. Prescribed Meclazine, flonase and Zyrtec. Symptoms still on going but improved.
Shortness of breath, intense chest pressure and pain, fainting, excessive sweating, dizziness
Sleepy, limp; pale, difficult to arouse, weak cry, given formula, approx 3 oz, sleepy again; Rxn persisent, during this time vital signs stable, R-18, T OK, color pale, pt lethargic p/1 hr pt more arousable, stronger, less limp; Sent home;
Patient felt dizzy and fell to the ground few minutes after while standing. Hit head left-side of occiput. Recovered quickly. Examined - small hematoma scalp.
Pain in my left arm where I received the shot, terrible Headache, internal fever, chills, tiredness, feeling of having a cold, feeling symtoms of vomiting, not wanted to eat.
tested positive for Covid-19; Lack of drug effect; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive for Covid-19) and DRUG INEFFECTIVE (Lack of drug effect) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Nov-2021, the patient experienced COVID-19 (tested positive for Covid-19) and DRUG INEFFECTIVE (Lack of drug effect). At the time of the report, COVID-19 (tested positive for Covid-19) and DRUG INEFFECTIVE (Lack of drug effect) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Nov-2021, SARS-CoV-2 test: positive (Positive) Positive.         Concomitant product included Vitamins. Patient got monoclonal antibody treatment.  Patient got second dose from batch number either 048A21A or 098A21A. Patient was scheduled to get the booster on 22 Nov 2021 but did not get it and advised to wait for 4 months by HCP. This is a spontaneous case concerning a 71-year-old female patient with no medical history reported, who experienced the unexpected event of COVID-19 and drug ineffective. The event occurred approximately 254 days after the second dose of the mRNA- 1273 vaccine. Patient received monoclonal antibody as treatment. The reporter's assessment was not provided. The rechallenge is not applicable since there's no information about the first dose. The benefit-risk relationship of the vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 71-year-old female patient with no medical history reported, who experienced the unexpected event of COVID-19 and drug ineffective. The event occurred approximately 254 days after the second dose of the mRNA- 1273 vaccine. Patient received monoclonal antibody as treatment. The reporter's assessment was not provided. The rechallenge is not applicable since there's no information about the first dose. The benefit-risk relationship of the vaccine is not affected by this report.
Information has been received from a RN concerning a female pt who in the last week of March or first week of April 2005, was vaccinated with a dose of Pneumovax 23. Concomitant therapy included Lovenox. Subsequently the pt developed a large hematoma at the injection site. The nurse stated that this may have been because the pt was on therapy with Lovenox. Unspecified medical attention was sought. The pt's outcome was unknown. No product quality complaint was involved. Additional information has been requested.
I woke up in the morning with a cold and minor nasal congestion, I had flown two days before to my home, went to an urgent care facility and tested positive for COVID-19.
A nurse reported the occurrence of a headache in a 51 year old female who was vaccinated with ehp B vaccine recombinant (Engerix B) for prophylaxis earlier than recommended. The subject had no relevant medical history and received no concomitant medications. On 1/29/03 and 2/5/03, the subject received her first and second injections of Engerix B (5377A) respectively. The second injection was received one week after the first injection. On 2/5/03, at an unspecified time post-immunization, the subject experienced a headache and saw "black spots." As of 2/10/03, the events persisted.
4 hrs p/vax parents reported 5 episodes lasting 5-10 seconds of fine tremors; no color changes; no altered conciousness; no focality, no facial charges-not sz activity by history; no fever at the time;
10 minutes after receiving vaccine, developed flushing and tingling of tongue. 45 minutes later, developed nausea. 1 hour and 45 minutes after vaccine, developed laryngitis.  Sent to ED for evaluation and treatment. Received Solumedrol and Pepsid in ED with improvement. Discharged home by or before 8pm with resolution of laryngitis and other symptoms. Reports "feeling great" this a.m.
After testing positive for Covid19 in the while on family visit. I developed Covid19 and slowly Pneumonia which got very bad and included severe sinusinfection. The person who infected me had Covid, but not Pneumonia. My symptoms needed medical attention where I begged the MD to give me AUGMENTIN. The medical system there is very different and confusing. However I suspected my symptoms to be a secondary bacterial infection. I had researched online which drugs woyld be legal and available within their system and saw Augmentin should be a possible option. Many drugs approved in hometown are over the counter are disallowed there. And I found myself fighting for my life while being ridiculled. Once I drove myself to the nearest hospital guided by GPS and on the promise of a GP MD that they had made an appointment for me, I was greeted by a locked door. I tried to explain my situation thru a glass door with an intercom. Once I stated the name of the MD and my family in said country, they let me in an started a physical exam, took blood and listened to my lungs. They confirmed the diagnosis by blood evidence and physical exam, but never took a radiograph or admitted me. They tried to offer me amoxiclilan and I told them I knew it would not be strong enough for what was going on. I was aware of the possibility of myocarditis or fluud around the heart, since I have had this condituon before, was very short of breath and had to spend the pruir 5 days in an upright positiin in bed
This spontaneous report as received from a other health professional refers to a patient of unknown age. Concomitant therapies included sterile diluent (MRK). On 29-JUN-2017 the patient was vaccinated with an improperly stored dose of M-M-R II (lot number M010426 expiration date: 01-MAR-2018, lot number: M032157 expiration date: 01-JUL-2018, lot number: M039913 expiration date: 26-SEP-2018) for prophylaxis (digital data logger). No adverse effects reported. This is one of several reports received from the same source. Sender's Comments: US-009507513-1708USA002800.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 1:56 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Oct-2021 at 1:56 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient's age was reported as 87.16 years.  No concomitant medications were reported.  Number of vials sent to clinic were 6. Out of which 2 vials were moved to fridge on 29-Sep-2021 and beyond use date for these vials was reported as 29-Oct-2021. Remaining 4 vials were moved to fridge on 05-Oct-2021 and beyond use date for these vials was reported as 04-Nov-2021. Product moved to clinic on 27-Oct-2021. Batch number 035C21A administered on 27-Oct-2021 underwent temperature excursion with temperature range of 29 and 32 degrees Fahrenheit at 09: 00 am and 10:00 am respectively.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  No treatment medications were reported.
Hive at injection site on right upper thigh with Varivax. Gave 3/4 teaspoon of 12.5 Diphenhydramine at 2:45 PM.
approx 4hr post vax, pt devel T of 102-103 deg F which was unresponsive to APAP , irritability & tenderness @ inject site.  one of three pt at this site to exp adverse event post vax.
5 weeks after vaccine my lips swelled up and blistered.  I was treated with a steroidal cream for 2 weeks and it went away but keeps coming back as soon as I stop the steroid